The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results from the first-in-human (FIH) phase I study of RO5520985 (RG7221), a novel bispecific human anti-ANG-2/anti-VEGF-A antibody, administered as an intravenous infusion to patients with advanced solid tumors.
Manuel Hidalgo
Research Funding - Roche
Christophe Le Tourneau
No relevant relationships to disclose
Christophe Massard
Consultant or Advisory Role - Roche
Research Funding - Roche
Valentina Boni
No relevant relationships to disclose
Emiliano Calvo
No relevant relationships to disclose
Joan Albanell
Consultant or Advisory Role - Roche (U)
Research Funding - Roche
Alvaro Taus
No relevant relationships to disclose
Marie-Paule Sablin
No relevant relationships to disclose
Andrea Varga
No relevant relationships to disclose
Ratislav Bahleda
No relevant relationships to disclose
Oliver Krieter
Employment or Leadership Position - Roche
Stock Ownership - Roche
Lada Markovtsova
Employment or Leadership Position - Roche
Stock Ownership - Roche
David Carlile
Employment or Leadership Position - Roche
Stock Ownership - Roche
Angelika Lahr
Employment or Leadership Position - Roche
Tapan Nayak
Employment or Leadership Position - Roche
Katharina Lechner
Employment or Leadership Position - Roche
Astrid Koehler
Employment or Leadership Position - Roche
Stock Ownership - Roche
Ingrid Van Uffelen
Employment or Leadership Position - Roche
Maria Martinez Garcia
No relevant relationships to disclose